Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Standardized assay for assessment of minimal residual disease in blood, bone marrow and apheresis from patients with plasma cell myeloma.

Blum A, Haussmann K, Streitz M, Schlickeiser S, Tietze-Buerger C, Blau IW, Uharek L.

Sci Rep. 2019 Feb 27;9(1):2922. doi: 10.1038/s41598-019-39631-2.

2.

Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation.

Schmidt V, Niederwieser D, Schenk T, Behre G, Klink A, Pfrepper C, Hinke A, Beelen DW, Junghanss C, Uharek L, Krüger WH, Hochhaus A, Sayer HG; East German Study Group for Hematology and Oncology (OSHO).

Bone Marrow Transplant. 2018 Sep;53(9):1188-1192. doi: 10.1038/s41409-018-0135-3. Epub 2018 Mar 15. No abstract available.

PMID:
29545592
3.

Epithelial barrier dysfunction as permissive pathomechanism in human intestinal graft-versus-host disease.

Troeger H, Hering NA, Bojarski C, Fromm A, Barmeyer C, Uharek L, Siegmund B, Fromm M, Rieger K, Schulzke JD.

Bone Marrow Transplant. 2018 Aug;53(8):1083-1086. doi: 10.1038/s41409-018-0144-2. Epub 2018 Mar 9. No abstract available.

PMID:
29523887
4.

Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies-the German Cancer Consortium approach.

Krackhardt AM, Anliker B, Hildebrandt M, Bachmann M, Eichmüller SB, Nettelbeck DM, Renner M, Uharek L, Willimsky G, Schmitt M, Wels WS, Schüssler-Lenz M.

Cancer Immunol Immunother. 2018 Apr;67(4):513-523. doi: 10.1007/s00262-018-2119-y. Epub 2018 Jan 29. Review.

PMID:
29380009
5.
6.

Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial.

Krämer I, Stilgenbauer S, Dietrich S, Böttcher S, Zeis M, Stadler M, Bittenbring J, Uharek L, Scheid C, Hegenbart U, Ho A, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P.

Blood. 2017 Sep 21;130(12):1477-1480. doi: 10.1182/blood-2017-04-775841. Epub 2017 Jul 17. No abstract available.

PMID:
28716861
7.

Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.

Neuenhahn M, Albrecht J, Odendahl M, Schlott F, Dössinger G, Schiemann M, Lakshmipathi S, Martin K, Bunjes D, Harsdorf S, Weissinger EM, Menzel H, Verbeek M, Uharek L, Kröger N, Wagner E, Kobbe G, Schroeder T, Schmitt M, Held G, Herr W, Germeroth L, Bonig H, Tonn T, Einsele H, Busch DH, Grigoleit GU.

Leukemia. 2017 Oct;31(10):2161-2171. doi: 10.1038/leu.2017.16. Epub 2017 Jan 16.

PMID:
28090089
8.

Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial.

Scheffold A, Jebaraj BMC, Jaramillo S, Tausch E, Steinbrecher D, Hahn M, Böttcher S, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P, Stilgenbauer S.

Br J Haematol. 2017 Oct;179(2):342-346. doi: 10.1111/bjh.14219. Epub 2016 Jul 8. No abstract available.

PMID:
27391907
9.

Advances in clinical NK cell studies: Donor selection, manufacturing and quality control.

Koehl U, Kalberer C, Spanholtz J, Lee DA, Miller JS, Cooley S, Lowdell M, Uharek L, Klingemann H, Curti A, Leung W, Alici E.

Oncoimmunology. 2015 Nov 11;5(4):e1115178. eCollection 2016 Apr.

10.

Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment.

Wieczorek A, Uharek L.

Biomark Insights. 2016 Feb 18;10(Suppl 3):49-54. doi: 10.4137/BMI.S22431. eCollection 2015. Review.

11.

Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO).

Kahl C, Krahl R, Becker C, Al-Ali HK, Sayer HG, Schulze A, Herold M, Hänel M, Scholl S, Hochhaus A, Uharek L, Maschmeyer G, Haehling D, Junghanß C, Peter N, Kämpfe D, Kettner E, Heinicke T, Fischer T, Kreibich U, Wolf HH, Niederwieser D.

J Cancer Res Clin Oncol. 2016 Jan;142(1):305-15. doi: 10.1007/s00432-015-2045-8. Epub 2015 Sep 25.

PMID:
26407768
12.

Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group.

Schroeder T, Rachlis E, Bug G, Stelljes M, Klein S, Steckel NK, Wolf D, Ringhoffer M, Czibere A, Nachtkamp K, Dienst A, Kondakci M, Stadler M, Platzbecker U, Uharek L, Luft T, Fenk R, Germing U, Bornhäuser M, Kröger N, Beelen DW, Haas R, Kobbe G.

Biol Blood Marrow Transplant. 2015 Apr;21(4):653-60. doi: 10.1016/j.bbmt.2014.12.016. Epub 2014 Dec 23.

13.

Randomised, double-blind, placebo-controlled trial of oral budesonide for prophylaxis of acute intestinal graft-versus-host disease after allogeneic stem cell transplantation (PROGAST).

Schmelz R, Bornhäuser M, Schetelig J, Kiani A, Platzbecker U, Schwanebeck U, Grählert X, Uharek L, Aust D, Baretton G, Schwerdtfeger R, Hampe J, Greinwald R, Mueller R, Ehninger G, Miehlke S.

BMC Gastroenterol. 2014 Nov 26;14:197. doi: 10.1186/s12876-014-0197-7.

14.

Single-Nucleotide Polymorphisms Within the Thrombomodulin Gene (THBD) Predict Mortality in Patients With Graft-Versus-Host Disease.

Rachakonda SP, Penack O, Dietrich S, Blau O, Blau IW, Radujkovic A, Isermann B, Ho AD, Uharek L, Dreger P, Kumar R, Luft T.

J Clin Oncol. 2014 Oct 20;32(30):3421-7. doi: 10.1200/JCO.2013.54.4056. Epub 2014 Sep 15.

PMID:
25225421
15.

Association between low uric acid levels and acute graft-versus-host disease.

Ostendorf BN, Blau O, Uharek L, Blau IW, Penack O.

Ann Hematol. 2015 Jan;94(1):139-44. doi: 10.1007/s00277-014-2180-3. Epub 2014 Aug 31.

PMID:
25172456
16.

Tracking in vivo dynamics of NK cells transferred in patients undergoing stem cell transplantation.

Killig M, Friedrichs B, Meisig J, Gentilini C, Blüthgen N, Loddenkemper C, Labopin M, Basara N, Pfrepper C, Niederwieser DW, Uharek L, Romagnani C.

Eur J Immunol. 2014 Sep;44(9):2822-34. doi: 10.1002/eji.201444586. Epub 2014 Jun 30.

17.

Immunotherapy: opportunities, risks and future perspectives.

Hildebrandt M, Peggs K, Uharek L, Bollard CM, Heslop HE.

Cytotherapy. 2014 Apr;16(4 Suppl):S120-9. doi: 10.1016/j.jcyt.2014.02.001. Review.

18.

Genetically modified T cells for the treatment of malignant disease.

Wieczorek A, Uharek L.

Transfus Med Hemother. 2013 Dec;40(6):388-402. doi: 10.1159/000357163. Epub 2013 Nov 29. Review.

19.

Rabbit antithymocyte globulin induces rapid expansion of effector memory CD8 T cells without accelerating acute graft versus host disease.

Wittenbecher F, Rieger K, Dziubianau M, Herholz A, Mensen A, Blau IW, Uharek L, Dörken B, Thiel A, Na IK.

Leuk Res Rep. 2013 Sep 27;2(2):82-5. doi: 10.1016/j.lrr.2013.09.001. eCollection 2013.

20.

Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial.

Koenigsmann M, Casper J, Kahl C, Basara N, Sayer HG, Behre G, Theurich S, Christopeit M, Mohren M, Reichle A, Metzner B, Ganser A, Stadler M, Uharek L, Balleisen L, Hinke A, Hinke R, Niederwieser D.

Bone Marrow Transplant. 2014 Mar;49(3):410-5. doi: 10.1038/bmt.2013.199. Epub 2013 Dec 23.

PMID:
24362366
21.

Combination of immunoglobulins and natural killer cells in the context of CMV and EBV infection.

Frenzel K, Lehmann J, Krüger DH, Martin-Parras L, Uharek L, Hofmann J.

Med Microbiol Immunol. 2014 Apr;203(2):115-23. doi: 10.1007/s00430-013-0321-2. Epub 2013 Dec 15.

PMID:
24337366
22.

Utilization of TREC and KREC quantification for the monitoring of early T- and B-cell neogenesis in adult patients after allogeneic hematopoietic stem cell transplantation.

Mensen A, Ochs C, Stroux A, Wittenbecher F, Szyska M, Imberti L, Fillatreau S, Uharek L, Arnold R, Dörken B, Thiel A, Scheibenbogen C, Na IK.

J Transl Med. 2013 Aug 14;11:188. doi: 10.1186/1479-5876-11-188.

23.

Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change.

Christopeit M, Kuss O, Finke J, Bacher U, Beelen DW, Bornhäuser M, Schwerdtfeger R, Bethge WA, Basara N, Gramatzki M, Tischer J, Kolb HJ, Uharek L, Meyer RG, Bunjes D, Scheid C, Martin H, Niederwieser D, Kröger N, Bertz H, Schrezenmeier H, Schmid C.

J Clin Oncol. 2013 Sep 10;31(26):3259-71. doi: 10.1200/JCO.2012.44.7961. Epub 2013 Aug 5.

PMID:
23918951
24.

Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation.

Schroeder T, Fröbel J, Cadeddu RP, Czibere A, Dienst A, Platzbecker U, Bug G, Uharek L, Fenk R, Germing U, Kröger N, Haas R, Kobbe G.

Leukemia. 2013 Sep;27(9):1910-3. doi: 10.1038/leu.2013.64. Epub 2013 Mar 1. No abstract available.

PMID:
23519388
25.

TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.

Dreger P, Schnaiter A, Zenz T, Böttcher S, Rossi M, Paschka P, Bühler A, Dietrich S, Busch R, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Stilgenbauer S.

Blood. 2013 Apr 18;121(16):3284-8. doi: 10.1182/blood-2012-11-469627. Epub 2013 Feb 22.

PMID:
23435461
26.

Immunological aspects of Candida and Aspergillus systemic fungal infections.

Mueller-Loebnitz C, Ostermann H, Franzke A, Loeffler J, Uharek L, Topp M, Einsele H.

Interdiscip Perspect Infect Dis. 2013;2013:102934. doi: 10.1155/2013/102934. Epub 2013 Jan 21.

27.

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.

Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T, Giagounidis A, Zohren F, Bruns I, Wolschke C, Rieger K, Fenk R, Germing U, Haas R, Kröger N, Kobbe G.

Leukemia. 2013 Jun;27(6):1229-35. doi: 10.1038/leu.2013.7. Epub 2013 Jan 14.

PMID:
23314834
28.

Molecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse.

Burmeister T, Molkentin M, Meyer C, Lachmann N, Schwartz S, Friedrichs B, Beyer J, Blau IW, Lohm G, Tietze-Bürger C, Marschalek R, Uharek L.

Exp Hematol Oncol. 2012 Apr 18;1(1):6. doi: 10.1186/2162-3619-1-6.

29.

Chronic graft versus host disease but not the intensity of conditioning has impact on survival after allogeneic hematopoietic stem cell transplantation for advanced hematological diseases.

Hilgendorf I, Wolff D, Nogai A, Kundt G, Hahn J, Holler E, Uharek L, Junghanss C, Leithäuser M, Thiel E, Freund M, Kahl C.

Onkologie. 2012;35(9):487-92. Epub 2012 Aug 13.

PMID:
23007145
30.

Rabbit antithymocyte globulin (thymoglobulin) impairs the thymic output of both conventional and regulatory CD4+ T cells after allogeneic hematopoietic stem cell transplantation in adult patients.

Na IK, Wittenbecher F, Dziubianau M, Herholz A, Mensen A, Kunkel D, Blau O, Blau I, Thiel E, Uharek L, Scheibenbogen C, Rieger K, Thiel A.

Haematologica. 2013 Jan;98(1):23-30. doi: 10.3324/haematol.2012.067611. Epub 2012 Jul 16.

31.

Detection of a novel HLA-A allele, designated A*02:334.

Schulze H, Todorova K, Cirocki J, Uharek L, Schönemann C.

Tissue Antigens. 2012 Aug;80(2):191. doi: 10.1111/j.1399-0039.2012.01900.x. Epub 2012 Jun 6.

PMID:
22671565
32.

Antiviral function and efficacy of polyvalent immunoglobulin products against CMV isolates in different human cell lines.

Frenzel K, Ganepola S, Michel D, Thiel E, Krüger DH, Uharek L, Hofmann J.

Med Microbiol Immunol. 2012 Aug;201(3):277-86. doi: 10.1007/s00430-012-0229-2.

PMID:
22297735
33.

Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning.

Casper J, Holowiecki J, Trenschel R, Wandt H, Schaefer-Eckart K, Ruutu T, Volin L, Einsele H, Stuhler G, Uharek L, Blau I, Bornhaeuser M, Zander AR, Larsson K, Markiewicz M, Giebel S, Kruzel T, Mylius HA, Baumgart J, Pichlmeier U, Freund M, Beelen DW.

Bone Marrow Transplant. 2012 Sep;47(9):1171-7. doi: 10.1038/bmt.2011.242. Epub 2011 Dec 12.

PMID:
22158386
34.

Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.

Wendtner CM, Hillmen P, Mahadevan D, Bühler A, Uharek L, Coutré S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de Parseval L, Hallek M, Heerema NA, Stilgenbauer S, Chanan-Khan AA.

Leuk Lymphoma. 2012 Mar;53(3):417-23. doi: 10.3109/10428194.2011.618232. Epub 2011 Nov 15.

PMID:
21879809
35.

A new HLA-B*52 allele, B*52:23, detected in a patient before bone marrow transplantation.

Todorova K, Schulze H, Ciroki J, Uharek L, Salama A, Schönemann C.

Tissue Antigens. 2011 Dec;78(6):455-6. doi: 10.1111/j.1399-0039.2011.01746.x. Epub 2011 Jul 18.

PMID:
21762112
36.

Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.

Ruutu T, Volin L, Beelen DW, Trenschel R, Finke J, Schnitzler M, Holowiecki J, Giebel S, Markiewicz M, Uharek L, Blau IW, Kienast J, Stelljes M, Larsson K, Zander AR, Gramatzki M, Repp R, Einsele H, Stuhler G, Baumgart J, Mylius HA, Pichlmeier U, Freund M, Casper J.

Haematologica. 2011 Sep;96(9):1344-50. doi: 10.3324/haematol.2011.043810. Epub 2011 Jun 9.

37.

Intrathecal application of donor lymphocytes in leukemic meningeosis after allogeneic stem cell transplantation.

Neumann M, Blau IW, Burmeister T, Tietze-Buerger C, Blau O, Gerbitz A, Uharek L, Thiel E.

Ann Hematol. 2011 Aug;90(8):911-6. doi: 10.1007/s00277-011-1171-x. Epub 2011 Feb 12.

PMID:
21318573
38.

MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease.

Heimesaat MM, Nogai A, Bereswill S, Plickert R, Fischer A, Loddenkemper C, Steinhoff U, Tchaptchet S, Thiel E, Freudenberg MA, Göbel UB, Uharek L.

Gut. 2010 Aug;59(8):1079-87. doi: 10.1136/gut.2009.197434.

PMID:
20639251
39.

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial.

Dreger P, Döhner H, Ritgen M, Böttcher S, Busch R, Dietrich S, Bunjes D, Cohen S, Schubert J, Hegenbart U, Beelen D, Zeis M, Stadler M, Hasenkamp J, Uharek L, Scheid C, Humpe A, Zenz T, Winkler D, Hallek M, Kneba M, Schmitz N, Stilgenbauer S; German CLL Study Group.

Blood. 2010 Oct 7;116(14):2438-47. doi: 10.1182/blood-2010-03-275420. Epub 2010 Jul 1.

PMID:
20595516
40.

Adoptive antifungal T cell immunotherapy--into the clinic?

Lehrnbecher T, Schmidt S, Koehl U, Schuster FR, Uharek L, Klingebiel T, Tramsen L.

Med Mycol. 2011 Apr;49 Suppl 1:S164-9. doi: 10.3109/13693786.2010.497953. Epub 2010 Jun 30.

PMID:
20586680
41.

Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study.

Bethge WA, Lange T, Meisner C, von Harsdorf S, Bornhaeuser M, Federmann B, Stadler M, Uharek L, Stelljes M, Knop S, Wulf G, Trenschel R, Vucinic V, Dittmann H, Faul C, Vogel W, Kanz L, Bunjes D.

Blood. 2010 Sep 9;116(10):1795-802. doi: 10.1182/blood-2010-02-270538. Epub 2010 Jun 7.

PMID:
20530284
42.

Impaired function of dendritic cells deficient in angiotensin II type 1 receptors.

Nahmod K, Gentilini C, Vermeulen M, Uharek L, Wang Y, Zhang J, Schultheiss HP, Geffner J, Walther T.

J Pharmacol Exp Ther. 2010 Sep 1;334(3):854-62. doi: 10.1124/jpet.109.161760. Epub 2010 Jun 1.

PMID:
20516139
43.

Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion.

Schmidt-Hieber M, Schwarck S, Stroux A, Ganepola S, Reinke P, Thiel E, Uharek L, Blau IW.

Int J Hematol. 2010 Jun;91(5):877-85. doi: 10.1007/s12185-010-0597-6. Epub 2010 May 21.

PMID:
20490728
44.

Cytogenetic studies in acute leukemia patients relapsing after allogeneic stem cell transplantation.

Schmidt-Hieber M, Blau IW, Richter G, Türkmen S, Bommer C, Thiel G, Neitzel H, Stroux A, Uharek L, Thiel E, Blau O.

Cancer Genet Cytogenet. 2010 Apr 15;198(2):135-43. doi: 10.1016/j.cancergencyto.2010.01.005. Erratum in: Cancer Genet Cytogenet. 2010 Jul 1;200(1):73.

PMID:
20362228
45.

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Kröger N, Holler E, Kobbe G, Bornhäuser M, Schwerdtfeger R, Baurmann H, Nagler A, Bethge W, Stelljes M, Uharek L, Wandt H, Burchert A, Corradini P, Schubert J, Kaufmann M, Dreger P, Wulf GG, Einsele H, Zabelina T, Kvasnicka HM, Thiele J, Brand R, Zander AR, Niederwieser D, de Witte TM.

Blood. 2009 Dec 17;114(26):5264-70. doi: 10.1182/blood-2009-07-234880. Epub 2009 Oct 7.

PMID:
19812383
46.

Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy.

Brestrich G, Zwinger S, Fischer A, Schmück M, Röhmhild A, Hammer MH, Kurtz A, Uharek L, Knosalla C, Lehmkuhl H, Volk HD, Reinke P.

Am J Transplant. 2009 Jul;9(7):1679-84. doi: 10.1111/j.1600-6143.2009.02672.x. Epub 2009 May 20.

47.

In vivo diagnosis of acute intestinal graft-versus-host disease by confocal endomicroscopy.

Bojarski C, Günther U, Rieger K, Heller F, Loddenkemper C, Grünbaum M, Uharek L, Zeitz M, Hoffmann JC.

Endoscopy. 2009 May;41(5):433-8. doi: 10.1055/s-0029-1214604. Epub 2009 May 5.

PMID:
19418398
48.

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.

Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, Hofmann WK, Uharek L, Thiel E, Scheibenbogen C.

Blood. 2009 Jun 25;113(26):6541-8. doi: 10.1182/blood-2009-02-202598. Epub 2009 Apr 23.

PMID:
19389880
49.

Angiotensin-(1-7) stimulates hematopoietic progenitor cells in vitro and in vivo.

Heringer-Walther S, Eckert K, Schumacher SM, Uharek L, Wulf-Goldenberg A, Gembardt F, Fichtner I, Schultheiss HP, Rodgers K, Walther T.

Haematologica. 2009 Jun;94(6):857-60. doi: 10.3324/haematol.2008.000034. Epub 2009 Apr 18.

50.

Limited penetration of posaconazole into cerebrospinal fluid in an allogeneic stem cell recipient with invasive pulmonary aspergillosis.

Reinwald M, Uharek L, Lampe D, Grobosch T, Thiel E, Schwartz S.

Bone Marrow Transplant. 2009 Aug;44(4):269-70. doi: 10.1038/bmt.2009.17. Epub 2009 Feb 16. No abstract available.

PMID:
19219077

Supplemental Content

Loading ...
Support Center